Samsara BioCapital’s Tango Therapeutics TNGX Stock Holding History

Samsara BioCapital’s Portfolio TNGX Stock Details TNGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-210,000	Closed	-$1.08M	–	30
2025 Q2	$1.08M	Sell	210,000 -420,000	-67%	-$1.04M	0.22%	23
2025 Q1	$863K	Hold	630,000	–	–	0.15%	26
2024 Q4	$1.95M	Hold	630,000	–	–	0.27%	29
2024 Q3	$4.85M	Hold	630,000	–	–	0.93%	22
2024 Q2	$5.41M	Hold	630,000	–	–	1.13%	21
2024 Q1	$5M	Hold	630,000	–	–	0.77%	23
2023 Q4	$6.24M	Hold	630,000	–	–	0.97%	21
2023 Q3	$7.09M	Hold	630,000	–	–	2.17%	13
2023 Q2	$2.09M	Hold	630,000	–	–	0.37%	29
2023 Q1	$2.49M	Hold	630,000	–	–	0.51%	29
2022 Q4	$4.57M	Hold	630,000	–	–	0.98%	23
2022 Q3	$2.28M	Hold	630,000	–	–	0.53%	34
2022 Q2	$2.85M	Hold	630,000	–	–	0.76%	28
2022 Q1	$4.78M	Hold	630,000	–	–	1.2%	21
2021 Q4	$6.89M	Sell	630,000 -70,000	-10%	-$842K	1.34%	19
2021 Q3	$9.05M	Buy	700,000 +200,000	+40%	+$2.4M	1.42%	18
2021 Q2	$5.69M	Hold	500,000	–	–	0.7%	27
2021 Q1	$5.56M	Hold	500,000	–	–	1.03%	22
2020 Q4	$5.72K	Hold	500,000	–	–	0.58%	20
2020 Q3	$5.18M	Buy	+500,000	New	+$5.11M	1.44%	17

Other funds holding TNGX

TGI

TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BCM

Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Samsara BioCapital's TNGX Position: Q3 2025 in Review

Samsara BioCapital sold out of Tango Therapeutics (TNGX) in Q3 2025, closing a stake of 210,000 shares — an estimated $1.08M sold.

Samsara BioCapital first reported a position in TNGX in Q3 2020 and held it in 20 quarters. The position peaked at $9.05M in Q3 2021. 141 funds tracked by Wall St. Rank hold TNGX as of Q3 2025.

Samsara BioCapital reported no remaining Tango Therapeutics position as of Q3 2025 after selling out during the quarter.
Samsara BioCapital sold 210,000 Tango Therapeutics shares in Q3 2025, an estimated $1.08M.
Samsara BioCapital first reported a position in Tango Therapeutics in Q3 2020 and held it in 20 quarters.
Samsara BioCapital's Tango Therapeutics position peaked at $9.05M in Q3 2021.
141 funds tracked by Wall St. Rank held Tango Therapeutics as of Q3 2025.

Based on Samsara BioCapital's 13F filing for Q3 2025, filed 14 Nov 2025.